MARKET

GTHX

GTHX

G1 Therapeutics
NASDAQ

Real-time Quotes | Nasdaq Last Sale

17.61
+0.64
+3.77%
Closed 16:14 06/01 EDT
OPEN
16.90
PREV CLOSE
16.97
HIGH
18.06
LOW
16.71
VOLUME
714.01K
TURNOVER
--
52 WEEK HIGH
41.80
52 WEEK LOW
8.80
MARKET CAP
664.55M
P/E (TTM)
-5.1076
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 7 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average GTHX stock price target is 65.60 with a high estimate of 82.00 and a low estimate of 51.00.

EPS

GTHX News

More
The Daily Biotech Pulse: FDA Nod For Roche's Combo Therapy In Liver Cancer, Allena Rips Higher, Pfizer To Invest Up To $500M In Biotechs
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 1)
Benzinga · 39m ago
G1 Therapeutics Announces Flexible Credit Financing for Up to $100 Million with Hercules Capital
GlobeNewswire · 15h ago
G1 Therapeutics Highlights Will Present Data Showing Myelopreservation Benefits To Trilaciclib In Patients With Small Cell Lung Cancer At ASCO
G1 Therapeutics, Inc. (NASDAQ:GTHX), a clinical-stage oncology company, today announced that data across three randomized, double-blind, placebo-controlled Phase 2 trials of the investigational therapy trilaciclib in
Benzinga · 05/13 22:03
G1 Therapeutics to Present Data Showing Myelopreservation Benefits of Trilaciclib in Patients with Small Cell Lung Cancer at the ASCO20 Virtual Scientific Program
- Trilaciclib significantly reduced myelosuppression and need for related supportive care interventions for patients with small cell lung cancer (SCLC) receiving chemotherapy -.
GlobeNewswire · 05/13 21:31
JP Morgan Maintains Overweight on G1 Therapeutics, Lowers Price Target to $23
JP Morgan maintains G1 Therapeutics (NASDAQ:GTHX) with a Overweight and lowers the price target from $33 to $23.
Benzinga · 05/12 15:21
G1 Therapeutics, Inc. (GTHX) CEO Mark Velleca on Q1 2020 Results - Earnings Call Transcript
Seeking Alpha - Transcript · 05/10 14:39
68 Stocks Moving In Thursday's Mid-Day Session
Gainers Tetraphase Pharmaceuticals, Inc. (NASDAQ: TTPH) shares jumped 114.4% to $2.9050 after falling 10% on Wednesday.
Benzinga · 05/07 16:42
G1 Therapeutics, Inc. (GTHX) Q1 2020 Earnings Call Transcript
Motley Fool · 05/07 15:30

Industry

Biotechnology & Medical Research
+0.07%
Pharmaceuticals & Medical Research
-0.77%

Hot Stocks

Symbol
Price
%Change

About GTHX

G1 Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing small-molecule therapies for the treatment of cancer. Its two clinical-stage candidates are trilaciclib (G1T28) and G1T38, which are potent, selective inhibitors of the validated kinase targets CDK4/6. Trilaciclib and G1T38 are designed to be combined and enhance the anti-tumor activity of current therapies. It is also developing G1T48, an oral selective estrogen receptor degrader (SERD) for the treatment of breast cancer. The Company is evaluating trilaciclib in three Phase II clinical trials. G1T38 is being evaluated in combination with Faslodex in a Phase I b/II a trial for patients with estrogen receptor-positive, HER2-negative breast cancer.
More

Webull offers kinds of G1 Therapeutics Inc stock information, including NASDAQ:GTHX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, GTHX stock news, and many more online research tools to help you make informed decisions.